| abstract |
The present invention is related to enhancing the function of anti-tumor antibodies by regulating FcyRIlB-mediated activity, In particular, disrupting SHIP activation by FcyRIIB enhances cytotoxicity elicited by a therapeutic antibody in vivo in a human. The invention further provides an antibody, e.g., an anti-tumor antibody, with a variant Fc region that results in binding of the antibody to FcyRllB with reduced affinity. A variety of transgenic mouse models demonstrate that the inhibiting FcyRIB molecule is a potent regulator of cytotoxicity in vivo. |